GlaxoSmithKline

Astellas Pharma joins SAFE-BioPharma

Friday, June 21, 2013 01:21 PM

Astellas Pharma has joined the SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the global SAFE-BioPharma digital identity and signature standard. As a member, Astellas is able to utilize the SAFE-BioPharma standard. It is the first Japanese pharmaceutical company to become a member.

More... »

HHS partners with GSK for new antibiotics

Wednesday, June 12, 2013 02:19 PM

GlaxoSmithKline and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), are collaborating to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.

More... »

MorphoSys, GSK ink license agreement

Thursday, June 6, 2013 01:35 PM

Pharmaceutical developer MorphoSys has entered into a global agreement with GlaxoSmithKline to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, which has concluded phase I/II development in mild to moderate rheumatoid arthritis.

More... »

FDA approves two GSK oral oncology treatments

Friday, May 31, 2013 11:31 AM

GlaxoSmithKline, a research-based pharmaceutical and healthcare company, announced the FDA has approved both Tafinlar (dabrafenib) and Mekinist (trametinib).

More... »

GSK acquires Okairos, strengthens vaccines business

Wednesday, May 29, 2013 02:44 PM

GlaxoSmithKline (GSK), a research-based pharmaceutical and healthcare company, has acquired Okairos, a specialist developer of vaccine platform technologies, for approximately $325 million in cash.

More... »

FDA approves GSK’s Breo Ellipta to treat COPD

Friday, May 17, 2013 01:25 PM

The FDA has approved GlaxoSmithKline and Theravance’s Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also approved to reduce exacerbations of COPD in patients with a history of exacerbations. 

More... »

GSK deal aims to grow business in Asia

Tuesday, May 14, 2013 01:30 PM

DKSH's Business Unit Healthcare, a market expansion services provider for healthcare companies seeking to grow their business in Asia, has signed an agreement with GlaxoSmithKline to provide contract sales services in both private clinics and trade channel for its antibiotic product line.

More... »

Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

Tuesday, May 14, 2013 01:12 PM

Elan has announced a royalty agreement with Theravance, by which Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs for which Theravance has partnered with GlaxoSmithKline, when and if received by Theravance.

More... »

JDRF appoints David E. Wheadon as executive vice president of research and advocacy

Thursday, May 9, 2013 12:04 PM

Juvenile Diabetes Research Foundation (JDRF), a global organization funding type 1 diabetes (T1D) research, has appointed David E. Wheadon, M.D., as its new executive vice president of research and advocacy.

More... »

BioDelivery Sciences appoints Thomas W. D'Alonzo to board of directors

Tuesday, April 30, 2013 08:00 AM

BioDelivery Sciences International, a specialty pharmaceutical company, has appointed Thomas W. D'Alonzo to the company's board of directors.

More... »